DeepCure, a Boston-based biotech firm, raised $24M in Series A-1 funding to enhance its AI-powered small molecule therapeutics.

The funding round was led by IAG Capital Partners, with contributions from existing investors. The capital will be used to further develop DeepCure's technology and progress its immunology and inflammation treatments toward clinical trials.

Founded by MIT researchers and led by CEO Kfir Schreiber, DeepCure leverages a generative AI and physics-based engine to accelerate drug discovery. The company also uses advanced automated chemistry synthesis to expand the diversity and volume of tested molecules.

DeepCure's innovative platform aims to revolutionize small molecule therapeutics, positioning it as a leader in the biotech industry.